A clinical-stage biotechnology company developing novel gene therapies that have the potential to improve and protect the lives of patients by enhancing their immune systems. Calimmune’s initial disease target is HIV/AIDS.
Calimmune Completes $15 Million Series B Financing
Calimmune has successfully completed a $15 million Series B financing round, led by a large pharmaceutical strategic investor. Alexandria Venture Investments also participated, joining existing investors including RA Capital Healthcare Fund LP and Translational Accelerator LLC. Read more